Allogene Therapeutics, Inc. (ALLO) Misses Q1 EPS by 6c

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q1 EPS of ($0.68), $0.06 worse than the analyst estimate of ($0.62). Revenue for the quarter came in at $50 thousand versus the consensus estimate of $9.73 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Keurig Dr Pepper coffee chief to depart ahead of planned split